KR102463617B1 - Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 - Google Patents
Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 Download PDFInfo
- Publication number
- KR102463617B1 KR102463617B1 KR1020187036486A KR20187036486A KR102463617B1 KR 102463617 B1 KR102463617 B1 KR 102463617B1 KR 1020187036486 A KR1020187036486 A KR 1020187036486A KR 20187036486 A KR20187036486 A KR 20187036486A KR 102463617 B1 KR102463617 B1 KR 102463617B1
- Authority
- KR
- South Korea
- Prior art keywords
- cancer
- oxo
- pharmaceutical composition
- leukemia
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012271 PD-L1 inhibitor Substances 0.000 title claims abstract description 41
- 229940121656 pd-l1 inhibitor Drugs 0.000 title claims abstract description 41
- 239000012270 PD-1 inhibitor Substances 0.000 title abstract description 36
- 239000012668 PD-1-inhibitor Substances 0.000 title abstract description 36
- 229940121655 pd-1 inhibitor Drugs 0.000 title abstract description 36
- 238000002648 combination therapy Methods 0.000 title abstract description 3
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 238000000034 method Methods 0.000 claims abstract description 27
- 208000006990 cholangiocarcinoma Diseases 0.000 claims abstract description 23
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 20
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 20
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims abstract description 16
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 14
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims abstract description 14
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims abstract description 13
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims abstract description 13
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims abstract description 13
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims abstract description 13
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 13
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims abstract description 13
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 claims abstract description 13
- 208000036566 Erythroleukaemia Diseases 0.000 claims abstract description 13
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 13
- 208000000172 Medulloblastoma Diseases 0.000 claims abstract description 13
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims abstract description 13
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims abstract description 13
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 13
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 13
- 206010039491 Sarcoma Diseases 0.000 claims abstract description 13
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 13
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 13
- 208000021841 acute erythroid leukemia Diseases 0.000 claims abstract description 13
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 13
- 229950009791 durvalumab Drugs 0.000 claims abstract description 13
- 208000005017 glioblastoma Diseases 0.000 claims abstract description 13
- 201000010536 head and neck cancer Diseases 0.000 claims abstract description 13
- 208000014829 head and neck neoplasm Diseases 0.000 claims abstract description 13
- 201000007270 liver cancer Diseases 0.000 claims abstract description 13
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 13
- 201000005202 lung cancer Diseases 0.000 claims abstract description 13
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 13
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 13
- 201000001441 melanoma Diseases 0.000 claims abstract description 13
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 13
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 13
- 201000000849 skin cancer Diseases 0.000 claims abstract description 13
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 12
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 12
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims abstract description 12
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims abstract description 12
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims abstract description 12
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims abstract description 12
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 12
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 claims abstract description 12
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 12
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims abstract description 11
- 229950002916 avelumab Drugs 0.000 claims abstract description 11
- 201000007450 intrahepatic cholangiocarcinoma Diseases 0.000 claims abstract description 11
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims abstract description 11
- YCBAQKQAINQRFW-UGSOOPFHSA-N 4,4,4-trifluoro-n-[(2s)-1-[[(7s)-5-(2-hydroxyethyl)-6-oxo-7h-pyrido[2,3-d][3]benzazepin-7-yl]amino]-1-oxopropan-2-yl]butanamide Chemical compound OCCN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)CCC(F)(F)F)C)C2=CC=CC=C2C2=CC=CN=C21 YCBAQKQAINQRFW-UGSOOPFHSA-N 0.000 claims abstract description 10
- 206010059352 Desmoid tumour Diseases 0.000 claims abstract description 10
- 201000006827 desmoid tumor Diseases 0.000 claims abstract description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 70
- 238000011282 treatment Methods 0.000 claims description 32
- 201000011510 cancer Diseases 0.000 claims description 29
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 10
- 229960003852 atezolizumab Drugs 0.000 claims description 10
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims description 10
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 6
- 238000001802 infusion Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000000527 lymphocytic effect Effects 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 20
- 210000004027 cell Anatomy 0.000 abstract description 16
- 229960003301 nivolumab Drugs 0.000 abstract description 16
- 229960002621 pembrolizumab Drugs 0.000 abstract description 15
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 abstract description 10
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 210000000214 mouth Anatomy 0.000 abstract 1
- 229940126062 Compound A Drugs 0.000 description 47
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 47
- 229940124597 therapeutic agent Drugs 0.000 description 12
- 108010070047 Notch Receptors Proteins 0.000 description 10
- 102000005650 Notch Receptors Human genes 0.000 description 10
- 230000011664 signaling Effects 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 230000000996 additive effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000003902 lesion Effects 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 3
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000036210 malignancy Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000010195 expression analysis Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000010212 intracellular staining Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000008823 permeabilization Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 231100000161 signs of toxicity Toxicity 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101001065556 Mus musculus Lymphocyte antigen 6G Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 208000017414 Precursor T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000010842 high-capacity cDNA reverse transcription kit Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 230000012177 negative regulation of immune response Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662339363P | 2016-05-20 | 2016-05-20 | |
| US62/339,363 | 2016-05-20 | ||
| PCT/US2017/032790 WO2017200969A1 (en) | 2016-05-20 | 2017-05-16 | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190008913A KR20190008913A (ko) | 2019-01-25 |
| KR102463617B1 true KR102463617B1 (ko) | 2022-11-03 |
Family
ID=58772978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187036486A Active KR102463617B1 (ko) | 2016-05-20 | 2017-05-16 | Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10688104B2 (enExample) |
| EP (1) | EP3458091B1 (enExample) |
| JP (1) | JP7194022B2 (enExample) |
| KR (1) | KR102463617B1 (enExample) |
| CN (2) | CN109475629A (enExample) |
| AU (1) | AU2017268187A1 (enExample) |
| BR (1) | BR112018073673A2 (enExample) |
| CA (1) | CA3025024A1 (enExample) |
| ES (1) | ES2904880T3 (enExample) |
| IL (1) | IL263110B (enExample) |
| MA (1) | MA45025A (enExample) |
| MX (1) | MX2018013941A (enExample) |
| SG (1) | SG11201810268YA (enExample) |
| WO (1) | WO2017200969A1 (enExample) |
| ZA (1) | ZA201807585B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| US10513558B2 (en) | 2015-07-13 | 2019-12-24 | Cytomx Therapeutics, Inc. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof |
| CA3020875A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer |
| RU2754452C2 (ru) | 2016-04-12 | 2021-09-02 | Эли Лилли Энд Компани | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака |
| ES2904880T3 (es) | 2016-05-20 | 2022-04-06 | Lilly Co Eli | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 |
| WO2018071307A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| MX2019009552A (es) | 2017-02-17 | 2019-10-02 | Hutchinson Fred Cancer Res | Terapias de combinacion para el tratamiento de canceres relacionados con el antigeno de maduracion de celulas b (bcma) y trastornos autoinmunitarios. |
| CA3080395A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
| JP2021506968A (ja) * | 2017-12-18 | 2021-02-22 | デビオファーム・インターナショナル・エス・アーＤｅｂｉｏｐｈａｒｍ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓ．Ａ． | 癌を治療するためのアゴニスト抗ＰＤ−１抗体とＧｎＲＨアゴニスト又はアンタゴニストとの併用 |
| WO2021084441A2 (en) * | 2019-10-28 | 2021-05-06 | Enzychem Lifesciences Corporation | Methods and compositions for treatment of cancer |
| AU2021443620A1 (en) * | 2021-04-28 | 2023-10-26 | Obi Pharma, Inc. | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014527042A (ja) * | 2011-07-27 | 2014-10-09 | イーライ リリー アンド カンパニー | ノッチ経路シグナリングインヒビター化合物 |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158355A0 (en) | 1996-12-23 | 2004-05-12 | Elan Pharm Inc | CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS beta-AMYLOID PEPTIDE RELEASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| EP1117778A2 (en) | 1998-10-02 | 2001-07-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein |
| BR0316880A (pt) | 2002-12-23 | 2005-10-25 | Wyeth Corp | Anticorpos contra pd-1 e usos dos mesmos |
| GB0303663D0 (en) * | 2003-02-18 | 2003-03-19 | Lorantis Ltd | Assays and medical treatments |
| EP2439273B1 (en) | 2005-05-09 | 2019-02-27 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) * | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007004743A1 (en) | 2005-07-05 | 2007-01-11 | Fujifilm Corporation | Copolymer and polymerizable composition |
| DE102006002966A1 (de) * | 2006-01-21 | 2007-07-26 | Schaeffler Kg | Laufscheibe mit integrierter Wälzkörperlaufbahn |
| WO2008112249A1 (en) | 2007-03-13 | 2008-09-18 | Trustees Of Columbia University In The City Of New York | Synergistic interaction of notch-1 inhibitors with glucocorticoids |
| CA3001152A1 (en) | 2007-03-28 | 2008-10-09 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| JP5385904B2 (ja) | 2007-08-14 | 2014-01-08 | イーライ リリー アンド カンパニー | γ−セクレターゼ阻害剤 |
| KR20140007979A (ko) | 2008-01-11 | 2014-01-20 | 에프. 호프만-라 로슈 아게 | 암 치료를 위한 감마-세크레타제 저해제의 용도 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| RS54233B1 (sr) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Kompozicije pd-1 antagonista i postupci za njihovu primenu |
| US8217149B2 (en) | 2008-12-09 | 2012-07-10 | Genentech, Inc. | Anti-PD-L1 antibodies, compositions and articles of manufacture |
| JO2885B1 (en) | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ | Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用 |
| WO2011026506A1 (de) | 2009-08-26 | 2011-03-10 | Frxsh Ag | Vorrichtung und verfahren zum mischen von mischgut |
| US8637493B2 (en) | 2009-11-12 | 2014-01-28 | University Of Massachusetts | Methods for treating glioblastoma |
| LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
| CN102085372A (zh) | 2009-12-04 | 2011-06-08 | 中国医学科学院基础医学研究所 | Notch通路抑制剂用于治疗mTOR活化导致的肿瘤的用途 |
| JP2013532153A (ja) * | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| JO3003B1 (ar) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | مركب أيميدازو [4، 5 -c ] كينولين-2- واحد واستخدامه كمثبط كيناز PI3/mtor |
| MY193562A (en) * | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| LT2785375T (lt) | 2011-11-28 | 2020-11-10 | Merck Patent Gmbh | Anti-pd-l1 antikūnai ir jų panaudojimas |
| JP6720075B2 (ja) * | 2013-05-31 | 2020-07-08 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 癌のための併用療法 |
| US9698876B2 (en) | 2013-07-23 | 2017-07-04 | Telefonaktiebolaget Lm Ericsson (Publ) | Transmission mode allocation in LTE networks |
| JP6586087B2 (ja) * | 2013-08-20 | 2019-10-02 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | Ｐｄ−１アンタゴニストとジナシクリブとの組合せでの癌治療 |
| GB201317929D0 (en) | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Chimeric antigen receptor |
| WO2015117164A1 (en) * | 2014-02-03 | 2015-08-06 | Memorial Sloan-Kettering Cancer Center | Tumor-associated macrophages and methods and compositions for targeting cancer therapy and identifying potential responders |
| US10092645B2 (en) * | 2014-06-17 | 2018-10-09 | Medimmune Limited | Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy |
| BR112017000130A2 (pt) | 2014-07-11 | 2018-01-09 | Genentech Inc | método para atenuar a toxicidade associada à inibição da via de notch e método de tratamento do câncer |
| JP7054622B2 (ja) | 2014-07-21 | 2022-04-14 | ノバルティス アーゲー | ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置 |
| US9465158B2 (en) * | 2014-09-04 | 2016-10-11 | National Taiwan Normal University | Light-guide coupler for modulating angular and spatial distributions of light source |
| CA2960824A1 (en) * | 2014-09-13 | 2016-03-17 | Novartis Ag | Combination therapies of alk inhibitors |
| BR112017008710A8 (pt) * | 2014-10-27 | 2023-04-25 | Hutchinson Fred Cancer Res | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva |
| ES2808153T3 (es) * | 2014-10-31 | 2021-02-25 | Mereo Biopharma 5 Inc | Terapia de combinación para tratamiento de enfermedad |
| PL3226897T3 (pl) | 2014-12-05 | 2021-08-30 | Memorial Sloan Kettering Cancer Center | Przeciwciała do celowania w antygen dojrzewania limfocytów b i sposoby ich zastosowania |
| WO2016164580A1 (en) | 2015-04-07 | 2016-10-13 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| TWI609687B (zh) | 2015-04-14 | 2018-01-01 | 美國禮來大藥廠 | 平滑肌肉瘤之標靶性治療 |
| MX2018000999A (es) | 2015-07-24 | 2018-11-09 | Oncotracker Inc | Moduladores de gamma secretasa para el tratamiento de disfuncion del sistema inmunologico. |
| RU2754452C2 (ru) | 2016-04-12 | 2021-09-02 | Эли Лилли Энд Компани | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака |
| CA3020875A1 (en) | 2016-04-12 | 2017-10-19 | Eli Lilly And Company | Combination therapy with notch and cdk4/6 inhibitors for the treatment of cancer |
| ES2904880T3 (es) | 2016-05-20 | 2022-04-06 | Lilly Co Eli | Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1 |
| CN109562114A (zh) | 2016-08-31 | 2019-04-02 | 伊莱利利公司 | 用于治疗实体瘤的给药方案 |
| WO2018071307A1 (en) | 2016-10-12 | 2018-04-19 | Eli Lilly And Company | Targeted treatment of mature t-cell lymphoma |
| US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| CA3080395A1 (en) | 2017-11-06 | 2019-05-09 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
-
2017
- 2017-05-16 ES ES17726073T patent/ES2904880T3/es active Active
- 2017-05-16 BR BR112018073673-2A patent/BR112018073673A2/pt unknown
- 2017-05-16 EP EP17726073.4A patent/EP3458091B1/en active Active
- 2017-05-16 CN CN201780044786.9A patent/CN109475629A/zh active Pending
- 2017-05-16 IL IL263110A patent/IL263110B/en unknown
- 2017-05-16 US US16/301,360 patent/US10688104B2/en active Active
- 2017-05-16 MX MX2018013941A patent/MX2018013941A/es unknown
- 2017-05-16 CA CA3025024A patent/CA3025024A1/en active Pending
- 2017-05-16 JP JP2018560759A patent/JP7194022B2/ja active Active
- 2017-05-16 CN CN202211692364.1A patent/CN115845070A/zh active Pending
- 2017-05-16 KR KR1020187036486A patent/KR102463617B1/ko active Active
- 2017-05-16 MA MA045025A patent/MA45025A/fr unknown
- 2017-05-16 WO PCT/US2017/032790 patent/WO2017200969A1/en not_active Ceased
- 2017-05-16 SG SG11201810268YA patent/SG11201810268YA/en unknown
- 2017-05-16 AU AU2017268187A patent/AU2017268187A1/en not_active Abandoned
-
2018
- 2018-11-12 ZA ZA2018/07585A patent/ZA201807585B/en unknown
-
2020
- 2020-05-08 US US16/870,853 patent/US11826317B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014527042A (ja) * | 2011-07-27 | 2014-10-09 | イーライ リリー アンド カンパニー | ノッチ経路シグナリングインヒビター化合物 |
Non-Patent Citations (1)
| Title |
|---|
| LIPSON, Evan J. et al.，Clinical Cancer Research，2013.01.15., vol 19, Issue 2，pp. 462-468 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3458091B1 (en) | 2021-11-17 |
| BR112018073673A2 (pt) | 2019-02-26 |
| JP2019516733A (ja) | 2019-06-20 |
| IL263110B (en) | 2022-07-01 |
| ZA201807585B (en) | 2024-09-25 |
| US20220008432A1 (en) | 2022-01-13 |
| IL263110A (en) | 2018-12-31 |
| AU2017268187A1 (en) | 2018-11-29 |
| SG11201810268YA (en) | 2018-12-28 |
| WO2017200969A1 (en) | 2017-11-23 |
| CA3025024A1 (en) | 2017-11-23 |
| MA45025A (fr) | 2019-03-27 |
| ES2904880T3 (es) | 2022-04-06 |
| CN115845070A (zh) | 2023-03-28 |
| EP3458091A1 (en) | 2019-03-27 |
| MX2018013941A (es) | 2019-03-21 |
| KR20190008913A (ko) | 2019-01-25 |
| US10688104B2 (en) | 2020-06-23 |
| US20190192531A1 (en) | 2019-06-27 |
| CN109475629A (zh) | 2019-03-15 |
| JP7194022B2 (ja) | 2022-12-21 |
| US11826317B2 (en) | 2023-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102463617B1 (ko) | Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법 | |
| JP7788114B2 (ja) | ヒトにおける固形腫瘍の処置のためのＣ．ｎｏｖｙｉ | |
| CN105873440B (zh) | 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途 | |
| US20240254120A1 (en) | Ep4 inhibitors and synthesis thereof | |
| US12295962B2 (en) | Polymorphic compounds and uses thereof | |
| JP2022044767A (ja) | 癌を処置する方法 | |
| JP2023533485A (ja) | 重症型の肺高血圧症の治療方法 | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2025516885A (ja) | ニロガセスタットを用いた治療 | |
| KR20230066401A (ko) | 항종양 치료법에서 면역 체크포인트 억제제와 조합된 치아우라닙의 용도 | |
| TW202214242A (zh) | 西奧羅尼或其衍生物在製備用於預防和/或治療非霍奇金淋巴瘤的藥物之用途 | |
| HK40004756A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| HK40004756B (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
| WO2020128054A1 (en) | Combination therapy for treatment of cancer | |
| RU2816314C1 (ru) | Виды комбинированной терапии для лечения рака | |
| WO2022105836A1 (en) | Combination therapies for treating cancer | |
| NZ788615A9 (en) | Dosing of a bruton's tyrosine kinase inhibitor | |
| EA047687B1 (ru) | Фармацевтическая комбинация для лечения рака | |
| NZ788180A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20181217 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20200515 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20220208 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20220808 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20221101 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20221101 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |